Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

[1]  A. Keech,et al.  The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study , 2015, Diabetologia.

[2]  A. Xu,et al.  Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. , 2015, The Journal of clinical endocrinology and metabolism.

[3]  M. Laakso,et al.  Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes , 2014, Diabetes Care.

[4]  M. Fasshauer,et al.  Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction , 2014, Clinical endocrinology.

[5]  Yuan Lin,et al.  Serum Fibroblast Growth Factor 21 Levels Are Correlated with the Severity of Diabetic Retinopathy , 2014, Journal of diabetes research.

[6]  Xiaokun Li,et al.  Attenuation of Hyperlipidemia- and Diabetes-Induced Early-Stage Apoptosis and Late-Stage Renal Dysfunction via Administration of Fibroblast Growth Factor-21 Is Associated with Suppression of Renal Inflammation , 2013, PloS one.

[7]  H. Fu,et al.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.

[8]  J. Kim,et al.  Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. , 2013, Endocrinology.

[9]  P. Galan,et al.  Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. , 2013, Atherosclerosis.

[10]  A. Xu,et al.  Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives , 2013, Clinical endocrinology.

[11]  A. Keech,et al.  Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  G. Backer,et al.  Do novel biomarkers add to existing scores of total cardiovascular risk? , 2012, European journal of preventive cardiology.

[13]  Y. Dong,et al.  Association between serum fibroblast growth factor 21 and diabetic nephropathy. , 2012, Metabolism: clinical and experimental.

[14]  S. Kliewer,et al.  Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ , 2012, Proceedings of the National Academy of Sciences.

[15]  S. Kliewer,et al.  Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones , 2012, Cell.

[16]  V. Gebski,et al.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[17]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[18]  Jian Xiao,et al.  Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile , 2010, PloS one.

[19]  M. Ai,et al.  [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[20]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[21]  Z. Varghese,et al.  An update on the lipid nephrotoxicity hypothesis , 2009, Nature Reviews Nephrology.

[22]  M. Laakso,et al.  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial , 2009, The Lancet.

[23]  M. Fasshauer,et al.  Serum Levels of the Adipokine FGF21 Depend on Renal Function , 2009, Diabetes Care.

[24]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[25]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[26]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[27]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[28]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[29]  A. Xu,et al.  Research Design and Methods , 2005, Hormone Research in Paediatrics.

[30]  James D. Best,et al.  The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] , 2004, Cardiovascular diabetology.

[31]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[32]  Therapies Study Investigators.  The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] , 2004 .